Ampicillin clinical pharmacology

Revision as of 20:57, 30 December 2013 by Mohamed Moubarak (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Ampicillin
AMPICILLIN® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]

Clinical Pharmacology

Ampicillin for Injection, USP diffuses readily into most body tissues and fluids. However, penetration into the cerebrospinal fluid and brain occurs only when the meninges are inflamed. Ampicillin is excreted largely unchanged in the urine and its excretion can be delayed by concurrent administration of probenecid. The active form appears in the bile in higher concentrations than those found in serum. Ampicillin is the least serum-bound of all the penicillins, averaging about 20% compared to approximately 60 to 90% for other penicillins. Ampicillin for Injection, USP is well tolerated by most patients and has been given in doses of 2 grams daily for many weeks without adverse reactions.[1]

References

  1. "AMPICILLIN (AMPICILLIN SODIUM) INJECTION, POWDER, FOR SOLUTION AMPICILLIN (AMPICILLIN SODIUM) INJECTION, POWDER, FOR SOLUTION [CLARIS LIFESCIENCES, INC.]". Text " accessdate" ignored (help)

Adapted from the FDA Package Insert.